宣泰医药：上半年净利润同比下降15.82% 拟每10股派0.25元

Core Insights - The company reported a revenue of 220 million yuan for the first half of 2025, reflecting a year-on-year growth of 0.74% [1] - The net profit attributable to shareholders decreased by 15.82% to 45.5857 million yuan, with basic earnings per share at 0.1 yuan [1] - The company plans to distribute a cash dividend of 0.25 yuan per 10 shares (tax included) to all shareholders [1] Revenue and Profit Analysis - The significant decline in sales revenue for the product Posaconazole enteric-coated tablets was attributed to its failure to win a bid in the 10th batch of centralized procurement scheduled for December 2024, leading to a 73.09% decrease in domestic sales revenue and a 28.54 percentage point drop in gross margin [1] - Sales revenue and profit-sharing income for Mesalazine enteric-coated tablets in the U.S. market fell by 58.36% and 19.90% respectively, due to increased competition from approved generic manufacturers and rising tariffs [1]